Patents Assigned to Trellis Bioscience, Inc.
-
Patent number: 12246063Abstract: Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.Type: GrantFiled: February 5, 2021Date of Patent: March 11, 2025Assignee: Trellis Bioscience, Inc.Inventors: Milton J. Friedman, Lawrence M. Kauvar
-
Publication number: 20240254258Abstract: Disclosed herein are monoclonal antibodies, and antigen-binding fragments thereof, that immunospecifically bind to human Anaplastic Lymphoma Kinase (ALK). Also provided are methods of use thereof, such the treatment of cancer. Also included are antibody-drug conjugates (ADCs) including the monoclonal antibodies and/or antigen-binding fragments thereof, linked to an effector agent, such as a cytotoxic agent. Also provided are method of using such ADCs. Nucleic acid molecules, vectors, and host cells for the monoclonal antibodies and antigen-binding fragments thereof are also provided, as are pharmaceutical and veterinarian compositions including the monoclonal antibodies, and antigen-binding fragments thereof, and/or the associated ADCs.Type: ApplicationFiled: December 19, 2023Publication date: August 1, 2024Applicant: Trellis Bioscience, Inc.Inventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence Kauvar
-
Publication number: 20240226877Abstract: The present disclosure relates to enhancements in diagnostic assays for detection of analytes. The improved assays are suitable for management of infections and pandemics in humans and animal reservoirs, including but not limited to SARS-CoV-2 (CoV2), and for measurement of biomarkers of disease (both human and veterinary).Type: ApplicationFiled: October 25, 2023Publication date: July 11, 2024Applicant: Trellis Bioscience, Inc.Inventors: Urs A. Ramel, Joel Blatt, Lawrence M. Kauvar, Stote Ellsworth, Ralph A. Tripp, Leslie P. Jones
-
Publication number: 20240150414Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: ApplicationFiled: August 19, 2023Publication date: May 9, 2024Applicants: Trellis Bioscience, Inc., The Regents of the University of CaliforniaInventors: Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
-
Publication number: 20240131508Abstract: The present disclosure relates to enhancements in diagnostic assays for detection of analytes. The improved assays are suitable for management of infections and pandemics in humans and animal reservoirs, including but not limited to SARS-CoV-2 (CoV2), and for measurement of biomarkers of disease (both human and veterinary).Type: ApplicationFiled: October 24, 2023Publication date: April 25, 2024Applicant: Trellis Bioscience, Inc.Inventors: Urs A. Ramel, Joel Blatt, Lawrence M. Kauvar, Stote Ellsworth, Ralph A. Tripp, Leslie P. Jones
-
Publication number: 20220204600Abstract: The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exarcebations of chronic obstructive pulmonary disease or chronic bronchitis are also provided.Type: ApplicationFiled: December 29, 2021Publication date: June 30, 2022Applicant: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Stefan Ryser
-
Publication number: 20120020980Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: ApplicationFiled: June 16, 2011Publication date: January 26, 2012Applicant: TRELLIS BIOSCIENCE, INC.Inventors: LAWRENCE M. KAUVAR, STOTE ELLSWORTH, WILLIAM USINGER, KRISTA MAUREEN MCCUTCHEON, YING-PING JIANG, FEN ZHANG, BO CHEN, GIZETTE SPERINDE, MINHA PARK, ORIT FOORD
-
Publication number: 20120020971Abstract: Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: ApplicationFiled: June 17, 2011Publication date: January 26, 2012Applicant: Trellis Bioscience, Inc.Inventors: Lawrence M. KAUVAR, Stote Ellsworth, William Usinger, Krista M. McCutcheon, Minha Park, Bo Chen, Ying-Ping Jiang
-
Patent number: 7939344Abstract: New applications for the use of distinguishable particulate labels available in a variety of hues and sized in the submicron range are described. These applications include profiling of cellular components, obtaining secretion patterns, identifying a multiplicity of components in chromatographic or electrophoretic techniques and identification of desired immunoglobulin secreting cells.Type: GrantFiled: August 8, 2008Date of Patent: May 10, 2011Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Remy Cromer, William D. Harriman, Ellen J. Collarini
-
Patent number: 7736648Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.Type: GrantFiled: October 24, 2008Date of Patent: June 15, 2010Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
-
Patent number: 7413868Abstract: New applications for the use of distinguishable particulate labels available in a variety of hues and sized in the submicron range are described. These applications include profiling of cellular components, obtaining secretion patterns, identifying a multiplicity of components in chromatographic or electrophoretic techniques and identification of desired immunoglobulin secreting cells.Type: GrantFiled: November 3, 2004Date of Patent: August 19, 2008Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Remy Cromer, William D. Harriman, Ellen J. Collarini
-
Patent number: 7238490Abstract: Intermolecular binding can be detected by formation of a “paratope” which results in an immediate generation of a signal. The substances to be tested for interaction are bound to demitopes, wherein said demitopes are components of a paratope which binds a reporter which provides said signal when bound. Known interactions measured in this way can also be employed to screen for compounds which interfere with the interactions. In addition to testing for individual interactions, the interaction of a compound with a library or library×library interactions can also be determined and the effect of potentially interfering substances evaluated.Type: GrantFiled: July 21, 2005Date of Patent: July 3, 2007Assignee: Trellis Bioscience, Inc.Inventor: Lawrence M. Kauvar
-
Patent number: 7060447Abstract: Intracellular translocation of proteins, particularly protein kinase C (PKC) isoenzymes, provides a surrogate test system for determining toxicity of candidate compounds. The profile of translocation with respect to at least one and preferably two or more signal transduction proteins can be correlated with-that of known toxins. In addition, databases of such profiles with respect to toxins of various types provide a useful set of standards for evaluating toxicity of candidate compounds. Moreover, to the extent that a toxin's profile mimics that found in a diseased state, the toxin can be used to construct screens for compounds alleviating the disease.Type: GrantFiled: November 13, 2003Date of Patent: June 13, 2006Assignee: Trellis Bioscience, Inc.Inventor: Lawrence M. Kauvar
-
Publication number: 20050266500Abstract: Intermolecular binding can be detected by formation of a “paratope” which results in an immediate generation of a signal. The substances to be tested for interaction are bound to demitopes, wherein said demitopes are components of a paratope which binds a reporter which provides said signal when bound. Known interactions measured in this way can also be employed to screen for compounds which interfere with the interactions. In addition to testing for individual interactions, the interaction of a compound with a library or library×library interactions can also be determined and the effect of potentially interfering substances evaluated.Type: ApplicationFiled: July 21, 2005Publication date: December 1, 2005Applicant: Trellis Bioscience, Inc.Inventor: Lawrence Kauvar
-
Patent number: 6936427Abstract: Intermolecular binding can be detected by formation of a “paratope” which results in an immediate generation of a signal. The substances to be tested for interaction are bound to demitopes, wherein said demitopes are components of a paratope which binds a reporter which provides said signal when bound. Known interactions measured in this way can also be employed to screen for compounds which interfere with the interactions. In addition to testing for individual interactions, the interaction of a compound with a library or library×library interactions can also be determined and the effect of potentially interfering substances evaluated.Type: GrantFiled: February 8, 2002Date of Patent: August 30, 2005Assignee: Trellis Bioscience, Inc.Inventor: Lawrence M. Kauvar
-
Patent number: 6867007Abstract: Effector functions are provided to a desired target with improved specificity by use of two or more complementary targeting components. The targeting components assemble a functional moiety at the target. At the target, the functional moiety itself provides an effector function or binds to additional components which provide an effector function. The effector function may be an enzymatic activity, a label or a signal. The binary or polynary targeting system may be used for analyte determination as well.Type: GrantFiled: April 30, 2003Date of Patent: March 15, 2005Assignee: Trellis Bioscience, Inc.Inventor: Lawrence M. Kauvar
-
Patent number: 6492125Abstract: Particulate labels that can be individually identified comprise particulate supports to which are bound at least two distinguishable signal-generating moieties, such as fluorophores emitting at different wavelengths, which signals are detectable and measurable in situ. By varying the ratio and/or amounts of the signal-generating moieties, a multiplicity of different and distinguishable labels is obtained. Each different label can then be coupled to a different reagent and the individual interactions of each reagent with a target observed in parallel.Type: GrantFiled: June 14, 1999Date of Patent: December 10, 2002Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, John Sedat
-
Patent number: 6444992Abstract: An apparatus for high resolution, high throughput, three-dimensional fluorescence microscopy with a rotatable circular disc for mounting samples to be viewed and multiple CCDs and beam splitters as detectors for the fluorescence emission.Type: GrantFiled: September 13, 1999Date of Patent: September 3, 2002Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, John Sedat